AI-generated summary
The authors randomized 30 post-treatment breast cancer survivors to daily bright blue-green light or dim red light, at either evening or morning timing, for 14 days. They report no significant between-group differences in symptoms or quality of life, though within-group improvements occurred in both arms. The study was small, and the authors state that the unexpected improvements in the dim-red control group remain unexplained.
- Participants
- 30
- Who or what was studied
- Women 1 to 3 years after chemotherapy and/or radiation for stage I to III breast cancer (mean age 52.5 years)
- Limits stated in the abstract
- The sample was small (30 women) and the authors note that unexpected symptom improvements in the dim-red control group remain unexplained and require further investigation.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Randomized controlled trial, Bright light therapy, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.